Table II. DPBA fluorescence is altered in tir1-1, ein2-5, and myb12.

Genotype	Treatment	Quercetin	Kaempferol	Q/K Ratio
		Relative DPBA Fluorescencea
Columbia	Untreated	1.00 ± 0.06	0.40 ± 0.02	2.50 ± 0.23
Columbia	IAA	3.14 ± 0.05b,c	1.04 ± 0.02b,c	3.03 ± 0.20
Columbia	ACC	1.63 ± 0.04b,c	1.32 ± 0.03b,c	1.24 ± 0.08b,c
Columbia	IAA and ACC	4.30 ± 0.13b,c	2.02 ± 0.07b,c	2.13 ± 0.35
tir1-1	Untreated	0.39 ± 0.02b	0.24 ± 0.02b	1.60 ± 0.10b
tir1-1	IAA	0.50 ± 0.05b	0.27 ± 0.04b	1.87 ± 0.26b
tir1-1	ACC	1.01 ± 0.09b,c	0.77 ± 0.06b,c	1.32 ± 0.08b,c
ein2-5	Untreated	0.60 ± 0.04b	0.20 ± 0.02b	3.00 ± 0.34
ein2-5	IAA	2.53 ± 0.18b,c	0.62 ± 0.06b,c	4.11 ± 0.45b,c
ein2-5	ACC	0.54 ± 0.08b	0.27 ± 0.02b,c	2.01 ± 0.21
myb12	Untreated	0.62 ± 0.03b	0.28 ± 0.02b	2.18 ± 0.18
myb12	IAA	0.74 ± 0.03b	0.29 ± 0.02b	2.53 ± 0.20
myb12	ACC	0.64 ± 0.03b	0.30 ± 0.02b	2.16 ± 0.23

^aNormalized DPBA fluorescence relative to Q-DPBA in untreated control is shown for samples treated for 8 h with 1 μm IAA or ACC. Mean ± se for greater than 15 individuals collected with identical settings is shown, as is the average Q/K ratio.

^bValues that are significantly different from the untreated wild type for each category (P < 0.05).

^cValues that are significantly different from the untreated control within a genotype within each category (P < 0.05).